Merck's KEYTRUDA (Pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
In: Contify Life Science News, 2018-01-08
Zeitungsartikel
Zugriff:
Titel: |
Merck's KEYTRUDA (Pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
|
---|---|
Zeitschrift: | Contify Life Science News, 2018-01-08 |
Veröffentlichung: | 2018 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|